Drugs codes by Medicare payment, 2023
Every code billed to Original Medicare Part B, with how many providers bill it and what it paid.
Top 200 drugs codes
The 200 with the most payment of 296 codes.
Not listed: 175 codes billed by fewer than 11 providers (small cells; each has its own page with the count).
| observed | calculated | calculated | calculated | calculated | calculated | ||
|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,204 | $2,354,722,372 | 17% | 3,427,458 | 722 | |
| J9271 | Injection, pembrolizumab, 1 mg | 1,841 | $1,154,350,197 | 8.2% | 27,083,045 | 12,400 | |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 2,039 | $967,501,751 | 6.9% | 33,468,979 | 9,900 | |
| J0897 | Injection, denosumab, 1 mg | 10,057 | $875,043,253 | 6.2% | 48,034,893 | 2,640 | |
| Q4262 | Dual layer impax membrane, per square centimeter | 141 | $834,254,090 | 5.9% | 900,953 | 1,358 | |
| 91322 | Descriptor not shown (CPT code) | 29,357 | $492,127,173 | 3.5% | 3,490,454 | 68 | |
| 90677 | Descriptor not shown (CPT code) | 52,451 | $436,258,344 | 3.1% | 1,572,263 | 21 | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 1,221 | $429,252,262 | 3.0% | 12,857,950 | 8,125 | |
| 91320 | Descriptor not shown (CPT code) | 27,083 | $422,068,649 | 3.0% | 3,323,183 | 60 | |
| 90662 | Descriptor not shown (CPT code) | 70,752 | $394,299,730 | 2.8% | 5,611,113 | 42 | |
| 90694 | Descriptor not shown (CPT code) | 51,679 | $365,021,262 | 2.6% | 4,923,384 | 50 | |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,208 | $281,806,783 | 2.0% | 1,556,832 | 649 | |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 615 | $229,940,934 | 1.6% | 6,102,727 | 8,100 | |
| Q4236 | Carepatch, per square centimeter | 79 | $223,639,047 | 1.6% | 229,182 | 1,650 | |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 848 | $214,619,140 | 1.5% | 55,220,402 | 48,400 | |
| J9299 | Injection, nivolumab, 1 mg | 505 | $211,141,098 | 1.5% | 9,040,661 | 14,740 | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 3,636 | $210,564,288 | 1.5% | 43,501,080 | 7,486 | |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 1,041 | $196,573,528 | 1.4% | 18,901,788 | 13,251 | |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 970 | $165,655,972 | 1.2% | 21,005,980 | 15,120 | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,352 | $144,851,522 | 1.0% | 5,598,259 | 2,926 | |
| J3262 | Injection, tocilizumab, 1 mg | 618 | $140,982,198 | 1.00% | 30,446,776 | 39,364 | |
| Q4217 | Woundfix, biowound, woundfix plus, biowound plus, woundfix xplus or biowound xplus, per square centimeter | 65 | $136,855,176 | 0.97% | 133,959 | 1,380 | |
| Q4253 | Zenith amniotic membrane, per square centimeter | 73 | $133,000,439 | 0.94% | 207,595 | 1,516 | |
| Q4205 | Membrane graft or membrane wrap, per square centimeter | 63 | $123,911,861 | 0.88% | 107,872 | 970 | |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 620 | $119,595,310 | 0.85% | 6,978,411 | 8,100 | |
| J3245 | Injection, tildrakizumab, 1 mg | 225 | $112,576,292 | 0.80% | 1,028,016 | 3,800 | |
| J2357 | Injection, omalizumab, 5 mg | 581 | $109,266,994 | 0.77% | 3,663,723 | 4,710 | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 542 | $98,127,656 | 0.70% | 2,757,687 | 3,524 | |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 373 | $95,848,193 | 0.68% | 442,174 | 675 | |
| J2785 | Injection, regadenoson, 0.1 mg | 6,388 | $92,688,873 | 0.66% | 2,186,558 | 208 | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 3,683 | $76,777,249 | 0.54% | 577,092 | 123 | |
| J2350 | Injection, ocrelizumab, 1 mg | 105 | $76,752,410 | 0.54% | 1,767,151 | 12,600 | |
| J9312 | Injection, rituximab, 10 mg | 317 | $74,353,284 | 0.53% | 1,198,227 | 3,100 | |
| Q4281 | Barrera sl or barrera dl, per square centimeter | 33 | $62,374,631 | 0.44% | 51,181 | 1,184 | |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 381 | $58,169,262 | 0.41% | 1,764,429 | 3,040 | |
| J1306 | Injection, inclisiran, 1 mg | 462 | $57,100,588 | 0.40% | 6,096,516 | 8,094 | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 180 | $53,562,091 | 0.38% | 1,410,709 | 3,615 | |
| Q4188 | Amnioarmor, per square centimeter | 47 | $49,849,322 | 0.35% | 66,963 | 966 | |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 490 | $49,839,096 | 0.35% | 415,159 | 555 | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 1,114 | $46,394,592 | 0.33% | 19,791,128 | 12,175 | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 1,209 | $40,672,606 | 0.29% | 46,709,069 | 27,750 | |
| J0517 | Injection, benralizumab, 1 mg | 200 | $39,638,328 | 0.28% | 304,123 | 1,230 | |
| J7327 | Hyaluronan or derivative, monovisc, for intra-articular injection, per dose | 1,365 | $37,304,978 | 0.26% | 67,439 | 32 | |
| J2182 | Injection, mepolizumab, 1 mg | 187 | $36,905,711 | 0.26% | 1,607,629 | 7,100 | |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 1,181 | $36,230,014 | 0.26% | 2,759,233 | 1,472 | |
| J1437 | Injection, ferric derisomaltose, 10 mg | 581 | $35,315,880 | 0.25% | 2,143,553 | 2,600 | |
| J1556 | Injection, immune globulin (bivigam), 500 mg | 46 | $35,204,320 | 0.25% | 627,002 | 6,350 | |
| J7326 | Hyaluronan or derivative, gel-one, for intra-articular injection, per dose | 1,610 | $34,994,949 | 0.25% | 87,015 | 35 | |
| Q4194 | Novachor, per square centimeter | 69 | $32,854,141 | 0.23% | 40,756 | 384 | |
| Q4186 | Epifix, per square centimeter | 122 | $26,992,894 | 0.19% | 229,031 | 675 |
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Descriptions of HCPCS Level II codes are the official CMS descriptors, shown verbatim; CPT codes show a ClaimLight category in place of the descriptor. Data year 2023.
Original Medicare Part B fee-for-service only; CMS suppresses provider lines with fewer than 11 beneficiaries. How these figures are computed